Zimmer Biomet
Price: 88.17Company and Business Model
Zimmer Biomet is a global leader in musculoskeletal healthcare, specializing in the design, manufacture, and marketing of orthopedic products. Its core offerings include joint reconstruction, spinal surgery, dental implants, and surgical instruments. The company operates primarily in the orthopedic and dental segments, with major revenue sources stemming from joint replacement and surgical solutions. Zimmer Biomet serves hospitals, outpatient surgery centers, and dental practices worldwide, focusing on improving patient outcomes through innovative technologies and solutions.
Investment Profile
Zimmer Biomet presents a balanced investment profile, appealing to investors seeking moderate growth and income through dividends. The company has a stable dividend yield, indicating a commitment to returning value to shareholders. Its recent revenue growth suggests potential for capital appreciation, while the moderate risk level may attract those with a balanced investment strategy.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 3.87 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- -7.0% ↓
- EPS surprise
- 1.7% in line
- 20d volatility
- 1.2% stable
- Dividend yield
- 1.3% moderate last ex-date: 2026-03-31
Track in portfolio
Price chart
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-09 02:56 | Sell | Hold | Mixed performance and fundamentals indicate caution. |
| 2026-05-30 02:55 | Hold | Sell | Weak momentum and high risk; cautious approach advised. |
| 2026-05-08 15:20 | — | Hold | Weak momentum and mixed fundamentals suggest caution. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-04-29 13:52 | Truist Financial | Target Lowered | 98 → 92 | 80.8 |
| 2026-04-29 11:31 | Canaccord Genuity | Target Lowered | 93 → 83 | 82.8 |
| 2026-04-29 11:21 | Stifel Nicolaus | Target Lowered | 110 → 105 | 82.8 |
Nothing yet